Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Bagsvaerd, Denmark
Employees
77,406
ISIN
US6701002056
Website
Novo Nordisk Metrics
BasicAdvanced
$308B
18.76
$3.70
0.21
$1.18
2.36%
Price and volume
Market cap
$308B
Beta
0.21
52-week high
$143.69
52-week low
$57.00
Average daily volume
8.8M
Dividend rate
$1.18
Financial strength
Current ratio
0.739
Quick ratio
0.542
Long term debt to equity
69.518
Total debt to equity
85.696
Dividend payout ratio (TTM)
48.61%
Interest coverage (TTM)
41.95%
Profitability
EBITDA (TTM)
24,444.965
Gross margin (TTM)
84.65%
Net profit margin (TTM)
34.51%
Operating margin (TTM)
48.43%
Effective tax rate (TTM)
20.93%
Revenue per employee (TTM)
$617,080
Management effectiveness
Return on assets (TTM)
23.29%
Return on equity (TTM)
88.12%
Valuation
Price to earnings (TTM)
18.756
Price to revenue (TTM)
6.463
Price to book
14.14
Price to tangible book (TTM)
67.17
Price to free cash flow (TTM)
26.346
Free cash flow yield (TTM)
3.80%
Free cash flow per share (TTM)
263.11%
Dividend yield (TTM)
1.70%
Forward dividend yield
2.36%
Growth
Revenue change (TTM)
24.11%
Earnings per share change (TTM)
17.93%
3-year revenue growth (CAGR)
26.70%
10-year revenue growth (CAGR)
12.46%
3-year earnings per share growth (CAGR)
29.74%
10-year earnings per share growth (CAGR)
15.18%
3-year dividend per share growth (CAGR)
29.91%
10-year dividend per share growth (CAGR)
16.38%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
CNBC·20 hours ago
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Reuters·21 hours ago
Novo Nordisk: Obesity war heating up, but Danish giant can still be a winner
Proactive Investors·23 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $308B as of July 09, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 18.76 as of July 09, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of July 09, 2025, the dividend rate is $1.1814 and the yield is 2.36%. Novo Nordisk has a payout ratio of 48.61% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.